US 11,052,097 B2
Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome
Georgios Tzortzis, Berkshire (GB); and Jelena Vulevic, Berkshire (GB)
Assigned to Clasado Research Services Limited
Appl. No. 14/130,883
Filed by Georgios Tzortzis, Berkshire (GB); and Jelena Vulevic, Berkshire (GB)
PCT Filed Jun. 20, 2012, PCT No. PCT/GB2012/051418
§ 371(c)(1), (2), (4) Date Jan. 3, 2014,
PCT Pub. No. WO2013/005001, PCT Pub. Date Jan. 10, 2013.
Claims priority of application No. 1111452 (GB), filed on Jul. 5, 2011.
Prior Publication US 2014/0142061 A1, May 22, 2014
Int. Cl. A61K 31/702 (2006.01); A61K 31/7016 (2006.01); A61P 31/06 (2006.01)
CPC A61K 31/702 (2013.01) [A61K 31/7016 (2013.01); A61P 31/06 (2018.01)] 5 Claims
 
1. A method for lowering levels of total cholesterol, triglycerides, and/or non-esterified fatty acids in a human, the method comprising administering to a human with elevated levels of total cholesterol, triglycerides, and/or non-esterified fatty acids an effective amount of a galactooligosaccharide composition comprising a mixture of galactooligosaccharides comprising disaccharides Gal (β1-3)-Glc; Gal (β1-3)-Gal; Gal (β1-6)-Gal; Gal (α1-6)-Gal; trisaccharides Gal (β1-6)-Gal (β1-4)-Glc; Gal (β1-3)-Gal (β1-4)-Glc; tetrasaccharide Gal (β1-6)-Gal (β1-6)-Gal (β1-4)-Glc and pentasacharide Gal (β1-6)-Gal (β1-6)-Gal (β1-6)-Gal (β1-4)-Glc;
wherein the galactooligosaccharide composition is administered without a probiotic strain.